Nonarteritic Anterior Ischemic Optic Neuropathy and Semaglutide: What is This All About?
Journal of The Association of Physicians of India · 2024
DOI: 10.59556/japi.72.0621 ↗Kurz gefasst
Editorial in der Zeitschrift Journal of The Association of Physicians of India, 2024. Verfasst von Awadhesh Kumar Singh und 2 weiteren Autor:innen. Beteiligte Einrichtung: Consultant Endocrinologist, Department of Diabetes & Endocrinology, G. D. Hospital & Diabetes Institute, Kolkata, West Bengal, India, Corresponding A…. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Optic Neuropathy, Ischemic. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 14 Literaturangaben.
Abstract (Originalsprache)
Nonarteritic anterior ischemic optic neuropathy (NAION) was first documented by a French physician Jean-Pierre Saint-Yves in 1817 (19th century). The clinical description of NAION was not known until 1935 when C. Miller Fischer thoroughly described it. Briefly, NAION is a rare (2.5-11.8 per 1,00,000 cases in men above 50 years) but serious condition that causes sudden painless loss of vision due to ischemia of the optic nerve.1 It is more common in Caucasians compared with Asians and is associated with various risk factors such as hypertension, type 2 diabetes (T2D), smoking, hyperlipidemia, obesity, obstructive sleep apnea, small optic nerve cup ("disk at risk"), optic nerve drusen, and certain drugs, especially phosphodiesterase type 5 inhibitors (PDE-5I), amiodarone, and cabergoline.2 Although the clinical development programs and real-world studies of semaglutide [a glucagon-like peptide-1 receptor agonist (GLP-1RA) approved for the treatment of T2D and obesity] did not report any significant increase in the risk of NAION, a recent retrospective cohort study suggested a possible link between NAION and semaglutide.3 This editorial briefly summarizes the current knowledge about NAION and its relation to metabolic disorders, cardiovascular, and antidiabetes drugs and puts a perspective concerning semaglutide.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Consultant Endocrinologist, Department of Diabetes & Endocrinology, G. D. Hospital & Diabetes Institute, Kolkata, West Bengal, India, Corresponding Author.
- Consultant Physician and Diabetes Specialist, Department of Diabetes & Endocrinology, Jothydev's Diabetes and Research Centre, Trivandrum, Kerala, India.
- Consultant Physician and Diabetes Specialist, Department of Diabetes & Endocrinology, Shilpa Medical Research Centre, Mumbai, Maharashtra, India.
Zitieren
APA
Singh, A. K., Kesavadev, J., & Tiwaskar, M. (2024). Nonarteritic Anterior Ischemic Optic Neuropathy and Semaglutide: What is This All About?. Journal of The Association of Physicians of India. https://doi.org/10.59556/japi.72.0621
Vancouver
Singh AK, Kesavadev J, Tiwaskar M. Nonarteritic Anterior Ischemic Optic Neuropathy and Semaglutide: What is This All About?. Journal of The Association of Physicians of India. 2024. doi:10.59556/japi.72.0621
BibTeX
@article{Singh2024,
author = {Singh, Awadhesh Kumar and Kesavadev, Jothydev and Tiwaskar, Mangesh},
title = {Nonarteritic Anterior Ischemic Optic Neuropathy and Semaglutide: What is This All About?},
journal = {Journal of The Association of Physicians of India},
year = {2024},
doi = {10.59556/japi.72.0621}
}
EUVIMED